A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS).
"This is the first phase III trial to report on the combination of chemotherapy, antiangiogenic treatment, and immunotherapy as first-line treatment for advanced non-squamous NSCLC," said lead author Professor Martin Reck, chief oncology physician, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Germany.
"The trial met its co-primary ...
A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS).
"This is the first phase III trial to report on the combination of chemotherapy, antiangiogenic treatment, and immunotherapy as first-line treatment for advanced non-squamous NSCLC," said lead author Professor Martin Reck, chief oncology physician, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Germany.
"The trial met its co-primary ...